The BCMA × CD3 bispecific met both primary endpoints in CERVINO, pairing strong efficacy with monthly IV dosing after a single step-up dose.
Key Takeaways
- AbbVie’s etentamig (ABBV-383) met both primary endpoints of objective response rate and progression-free survival in the Phase 3 CERVINO trial.
- Etentamig achieved a 74.0% objective response rate versus 45.7% with standard available therapies and reduced the risk of progression or death by 60% (HR 0.40; 95% CI, 0.29–0.54).
- The competitive story extends beyond efficacy: etentamig uses a single step-up dose followed by once-every-four-weeks IV dosing, potentially reducing visit frequency in a BCMA bispecific market that already includes several approved products. (AbbVie CERVINO topline results)
Data Snapshot
| Metric | Etentamig | Standard available therapies |
|---|---|---|
| Patients analyzed at data cutoff | 393 total | — |
| Median prior lines | 3 | 3 |
| Median follow-up | 11.4 months | 11.4 months |
| Objective response rate | 74.0% | 45.7% |
| ORR p-value | <0.0001 | — |
| Progression-free survival | HR 0.40 | Reference |
| PFS 95% CI | 0.29–0.54 | — |
| 12-month overall survival | 87.9% | 72.0% |
| OS HR | 0.48 | Reference |
| Grade 3/4 infections | 27.7% | 19.2% |
| Grade 5 infections | 1.5% | 3.1% |
| CRS with single step-up regimen | 28.3% | — |
| Grade ≥3 CRS | 0% reported | — |
| Dosing | Single step-up → IV Q4W | Regimen dependent |
CERVINO provides randomized Phase 3 evidence that etentamig can improve both response rate and progression-free survival in triple-class exposed relapsed or refractory multiple myeloma.
What Happened
AbbVie reported positive topline results from CERVINO, a randomized, open-label Phase 3 study comparing etentamig with investigator-selected standard available therapies in relapsed or refractory multiple myeloma.
Patients had received at least two prior treatment lines and had previously been exposed to all three major treatment classes: a proteasome inhibitor, an immunomodulatory drug and an anti-CD38 monoclonal antibody.
At a median follow-up of 11.4 months, etentamig produced an objective response in 74.0% of patients versus 45.7% with standard therapy. Progression-free survival also favored etentamig, with an HR of 0.40, corresponding to a 60% reduction in the risk of progression or death.
Overall survival is encouraging but remains immature. Twelve-month survival was 87.9% versus 72.0%, with an HR of 0.48, but the prespecified efficacy boundary for OS had not been crossed at the interim analysis.
Safety is less straightforward. CRS occurred in 28.3% of patients receiving the single step-up regimen, predominantly as Grade 1 events, and no Grade 3 or higher CRS was reported. However, Grade 3/4 infections occurred in 27.7% with etentamig versus 19.2% with standard therapy, so the topline data do not support describing etentamig broadly as safer.
Full CERVINO data are expected at the International Myeloma Society Annual Meeting later in September 2026. Fierce Biotech highlighted AbbVie’s emphasis on monthly dosing and the possibility of extending treatment beyond highly specialized centers. (Fierce Biotech analysis)
Why It Matters
Etentamig is entering a market where BCMA × CD3 T-cell redirection is already clinically validated.
That means AbbVie does not simply need to prove that the mechanism works. It needs to show that etentamig can offer a competitive balance of efficacy, safety and treatment convenience.
| Product | Company | Target | U.S. status | Dosing characteristic |
|---|---|---|---|---|
| Etentamig (ABBV-383) | AbbVie | BCMA × CD3 | Phase 3 positive; investigational | Single step-up → IV Q4W |
| Tecvayli (teclistamab) | J&J | BCMA × CD3 | FDA traditional approval | Step-up dosing; ongoing treatment |
| Elrexfio (elranatamab) | Pfizer | BCMA × CD3 | FDA accelerated approval | SC step-up → weekly → Q2W; selected patients can later reach Q4W |
| Lynozyfic (linvoseltamab) | Regeneron | BCMA × CD3 | FDA accelerated approval | IV step-up → weekly → Q2W; selected responders can later reach Q4W |
Tecvayli’s original accelerated approval was converted to traditional FDA approval in March 2026, and the agency also approved Tecvayli combined with Darzalex after at least one prior line of therapy. This gives J&J an important head start in moving BCMA-directed treatment earlier in the disease course. (FDA Tecvayli approval)
Pfizer’s Elrexfio remains under accelerated approval and uses subcutaneous step-up dosing followed by weekly treatment, with eligible responders moving to Q2W and later Q4W dosing. (FDA Elrexfio prescribing information)
Regeneron’s Lynozyfic received accelerated FDA approval in July 2025. Its IV regimen uses step-up dosing followed by weekly and then biweekly treatment, with Q4W dosing available for selected patients maintaining at least a very good partial response. (FDA Lynozyfic approval)
Etentamig’s proposed convenience advantage therefore needs nuance. Monthly dosing begins early after a single step-up dose, but the drug is administered intravenously, whereas Tecvayli and Elrexfio are subcutaneous therapies. Dosing frequency alone is not the whole convenience story.
BioPharma Dive noted that AbbVie is entering behind J&J, Pfizer and Regeneron and is increasingly positioning etentamig around treatment burden and safety rather than a fundamentally new target. (BioPharma Dive competitive view)
The Science Behind Etentamig
Etentamig shares the same broad BCMA × CD3 mechanism as several approved competitors, but its molecular architecture is different.
It combines bivalent, high-avidity BCMA binding, low-affinity CD3 engagement and retained FcRn binding—features intended to preserve tumor targeting, moderate T-cell activation and support longer systemic exposure.
Why engineer a BCMA bispecific this way?
Read the BP Science explainer:
How Etentamig Redirects T Cells in Multiple Myeloma
BP View
Etentamig’s Phase 3 result establishes it as a credible late entrant into the BCMA bispecific market, but the 74% response rate alone is unlikely to determine its commercial position.
The more practical differentiation is the treatment schedule. A single step-up dose followed by monthly IV administration could reduce visit frequency compared with regimens that require multiple step-up doses or extended weekly treatment. At the same time, the IV route means convenience should be assessed alongside infusion time, monitoring requirements and the subcutaneous options already available.
Safety also remains nuanced. The 28.3% CRS rate with no Grade 3 or higher events is encouraging, but the higher rate of Grade 3/4 infections versus standard therapy means it is premature to call etentamig broadly safer than other BCMA bispecifics.
The next value opportunity may come from broader use rather than from the current late-line monotherapy setting alone. AbbVie is already evaluating etentamig in combination strategies, and positive Phase 3 data could support development in earlier lines of multiple myeloma. Additional opportunities may also emerge in other BCMA-expressing plasma-cell disorders, provided efficacy and safety remain consistent across broader patient populations.
If monthly dosing proves practical in routine care, those combination and earlier-line programs could ultimately determine whether etentamig becomes a meaningful part of AbbVie’s multiple myeloma franchise rather than simply another late-line BCMA bispecific.
Related Post
For another multiple myeloma strategy, read my previous analysis of Tecvayli plus Darzalex and the combination of BCMA-directed T-cell engagement with CD38 targeting.
About BP
Biopharma Perspective (BP) explains global biopharma news through strategic, clinical and market perspectives.
Have a different view on this analysis or something you’d like to discuss? Leave a comment — I’d be happy to hear your thoughts.
Leave a Reply